Targeted treatment of pediatric OSA was associated with significant improvement in sleep-disordered breathing and biochemical markers of liver injury in children with obesity and MASLD. Clinically meaningful improvement in ALT was independently associated with CPAP therapy and better nocturnal oxygenation, supporting the hypothesis that correction of intermittent hypoxemia may contribute to hepatic recovery. These findings identify OSA as a potentially modifiable contributor to pediatric MASLD a
Conditions
Interventions
Adenotonsillectomy was performed in children with adenotonsillar hypertrophy and moderate-to-severe OSA. Continuous positive airway pressure (CPAP) therapy was prescribed for children with severe OSA
Experimental Procedure/Surgery,No Intervention No treatment
Targeted treatment group,Non-targeted treatment group
Sponsors
Chonburi Hospital
Eligibility
Sex/Gender
All
Age
4 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Children aged between 4 and 18 years 2. Obesity is defined as a body mass index (BMI) z-score greater than 2 3. Diagnosis of OSA confirmed by overnight polysomnography 4. Evidence of hepatic steatosis on abdominal ultrasonography
Exclusion criteria
Exclusion criteria: 1. Other liver diseases such as viral hepatitis (hepatitis B or C infection), autoimmune liver disease, or inherited metabolic liver disorders 2. History of use of hepatotoxic medications 3. Chronic systemic diseases known to affect liver function
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in liver injury 6 to 12 months after end of the intervention Reduction in serum alanine aminotransferase (ALT) concentration | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in severity of OSA and hepatic steatosis 6 to 12 months after end of the intervention Polysomnographic parameters and hepatic steatosis grade on abdominal ultrasonography | — |
Countries
Thailand
Contacts
Public ContactWoranart Ratanakorn
Chonburi Hospital
Outcome results
None listed